Platelet aggregation and hemostasis pathways (N/A)

Platelet aggregation and hemostasis pathways are the physiological mechanisms that prevent blood loss and maintain vascular integrity following injury (StatPearls, 2023). These pathways involve a coordinated sequence of events starting with primary hemostasis, where platelets adhere to the damaged vessel wall, become activated, and aggregate to form a platelet plug (PMC, 2022). This is followed by secondary hemostasis, or the coagulation cascade, which results in the generation of thrombin and the conversion of fibrinogen to fibrin, stabilizing the clot (NIH, 2021). Dysregulation of these pathways is central to the pathogenesis of arterial and venous thrombosis, leading to life-threatening conditions such as myocardial infarction, ischemic stroke, and pulmonary embolism (MDPI, 2023). Conversely, deficiencies in these pathways result in bleeding disorders like hemophilia or von Willebrand disease (StatPearls, 2023). Therapeutic strategies targeting these pathways include antiplatelet agents that inhibit platelet activation and anticoagulants that interfere with the coagulation cascade, both of which are essential for managing cardiovascular and thromboembolic risks (Drugs.com, 2024). Monitoring these pathways through biomarkers like prothrombin time and platelet function tests is critical for ensuring therapeutic efficacy and patient safety (PMC, 2023).

Other names

Primary hemostasisSecondary hemostasisCoagulation cascadePlatelet activation pathwaysThrombosis pathways

Inhibition of cyclooxygenase-1 (COX-1), antagonism of P2Y12 purinergic receptors, inhibition of Factor Xa, direct inhibition of thrombin, and blockade of glycoprotein IIb/IIIa (GPIIb/IIIa) receptors.